Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ...

The triplet regimen of berdomide, daratumumab (Darzalex), and dexamethasone has led to deepening responses in newly diagnosed, transplant-ineligible patients with multiple myeloma.

Anbenitamab combined with chemotherapy significantly improved PFS and OS in HER2-positive gastric or GEJ cancer patients compared to chemotherapy alone. The trial showed a 75% reduction in progression ...